Nasdaq

StemRIM Begins Phase 2 Trial for Cardiomyopathy Treatment

StemRIM Inc. has commenced a Phase 2 clinical trial for its regenerative medicine product, Redasemtide, targeting ischemic cardiomyopathy at Osaka University Hospital. This trial aims to evaluate the ...
Medscape

DEFINITE: Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation

The Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial was conducted to evaluate the prophylactic implantation of an ICD to prevent sudden death in patients with ...
Nasdaq

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of ...
Business Wire

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has issued a ...
Business Wire

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) ...
Healio

Optimizing mavacamten for treatment of obstructive hypertrophic cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten)SOUTH SAN FRANCISCO, ...
Yahoo Finance

Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic ...

MISSISSAUGA, ON, March 2, 2026 /CNW/ - Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi ...
Seeking Alpha

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...